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Abstract 
A rat urokinase receptor (uPAR) cDNA fragment was amplified by RT-PCR from RNA of the rat osteoblastic ell line CFK-1. Using this DNA 
species as a hybridization probe two rat uPAR cDNAs were isolated from a CFK-1 cDNA library. These two cDNAs encode an identical uPAR 
protein except for a single base mutation which results in the substitution of cysteine to serine at amino acid 71 in one variant. PCR analysis of rat 
genomic DNA revealed the presence of an additional uPAR arising from alternate splicing which is expressed in a variety of tissues. These studies 
provide the tools for examining uPAR function in fibrinolysis, tumor invasion and metastasis in the rat and for identifying the mechanism of species 
specificity in uPA actions. 
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1. Introduction 
Urinary plasminogen activator or urokinase (UPA) be- 
longs to the family of serine proteases which cause fibri- 
nolysis by plasminogen activation and is also believed to 
play a major role in tumor invasion and metastasis [ 141. 
It is produced by various tumors and tumor cell lines 
including prostate cancer and the prostate cancer cell 
PC-3 [5]. Binding of UPA to a cell surface receptor is 
essential for activation of plasminogen and for site di- 
rected extracellular proteolysis by tumors which produce 
this protease [6,7]. In previous studies we have also 
shown that UPA can act as a growth factor for the cells 
of the osteoblast phenotype [5] and have localized these 
effects of UPA within its receptor binding domain i.e. 
amino acids 4-43. Furthermore fucosylation of UPA at 
Thr’* was shown to be critical for these effects [8]. 
Recently cDNAs encoding human and mouse UPA 
receptors (uPARs) have been isolated [9,10]. These are 
cysteine rich highly glycosylated 5&60 kDa proteins at- 
tached to the cell membrane by a glycosyl-phosphotidy- 
linositol (GPI) anchor. The mature uPAR consists of 
three domains of internal homology. In addition, the 
NH,-terminal 87 residues are believed to constitute the 
uPA binding domain. In both the human and the mouse, 
variant uPARs have been cloned which are believed to 
*Corresponding author. Correspondence address: Room H4.72, Royal 
Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada, 
H3A lA1. 
0014-5793/94/%7.00 0 1994 Federation of European Biochemical Societies, 
SSDZ 0014-5793(93)El480-A 
be due to alternative splicing. These isoforms differ from 
the original uPARs in their carboxy-terminal regions. In 
both species however, the alternatively spliced forms re- 
tain the critical NH,-terminal ligand binding domain 
[ 111. By in situ hybridization the alternately spliced forms 
of uPARs have been reported to be differentially ex- 
pressed in the mouse gastrointestinal tract [lo]. 
In the present study we report the isolation and char- 
acterization of two uPAR isoforms from the rat osteob- 
lastic cell line, CFK-1, which differ by a single amino 
acid within their critical ligand binding domain. Further- 
more analysis of rat genomic DNA demonstrates the 
presence of an additional rat uPAR isoform resulting 
from alternate splicing in the second repeat of the uPAR. 
This alternately spliced receptor is expressed in multiple 
rat tissues. 
2. Materials and methods 
2.1. Materials 
All PCR reactions were performed in a Gene amp PCR 9600 appara- 
tus, Perkin-Elmer-Cetus Norwalk, CT. The rat osteoblastic ell line, 
CFK-1, which was employed has previously been described [12]. The 
CFK-1 cDNA library was a generous gift from Dr. John Wozney, 
Genetics Institute, Cambridge, MA. 
2.2. PCR amplification of rat uPAR 
Total cellular RNA was isolated from CFK-1 cells using 6M gua- 
nidium thiocyanate-phenolchloroform extraction. 3 pg of total RNA 
was used for reverse transcription using random primer (Pharmacia) 
and 200 units of reverse transcriptase (BRL) in a final volume of 20 ~1 
and incubating at 23°C for 10 min, at 42°C for 50 min and at 70°C for 
15 min. Rat uPAR cDNA was amplified using two PCR primers 1 and 
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2 corresponding to nucleotides 521-538 and 1034-1051, respectively, 
of the reported nucleotide sequence of human uPAR 19,131. The PCR 
reaction-included 30 cycles of denaturation (90°C, 20 s), annealing 
(50°C. 30 sj. and extension (72°C. 60 s). followed bv a final (10 min) ,, \ ,, 
extension step in a volume of lOO@. One-tenth of the reaction mixture 
was analyzed by electrophoresis on a 1.1% DNA agarose gel and then 
visualized by ethidium bromide staining to identify the amplified DNA 
products. 
To identify the alternately spliced rat uPAR, 1 pg of rat genomic 
DNA was isolated from CFK-1 cells and subjected to PCR using two 
flanking primers, A (5’~GAGCAAAGCCTGCAG-3’) and B (5’- 
TTGCTATGGAAACC-3’) which were svnthesized based on the re- 
ported nucleotide sequence of the alternately spliced form of mouse 
uPAR [lo]. To examine the tissue specific expression of this uPAR 
isoform 3 pg of total RNA was extracted from CFK-1 cells, kidney, 
liver and brain and analvzed bv RT-PCR using mimers A and B as 
described above. All PCR react&s were analyzed on 1.1% DNA aga- 
rose gel containing ethidium bromide. 
2.3. cDNA cloning 
The amplified rat specific uPAR DNA fragment was labeled with 
13’P]dCTP by the random primer method 1141. 1x lo6 plaques from a 
CFK-I cDN_A library in lambda ZAP vector were screened on duplicate 
filters (Amersham) at 40°C in 50% formamide. After 24 h incubation, 
filters were washe four times for 20 min, each with 1 x SSC (10 x SSC 
= 1.5 M NaCI, 0.5 M sodiumcitrate, pH 7.0), 0.1% SDSat 40°C [15,16]. 
Autoradiography of filters was carried out at -70°C using XAR film 
(Kodak Co, Rochester, NY) with two intensifying screens. 
3. Results 
3.1. Amplijication of rat uPAR DNA 
Using RT-PCR a predicted 520-bp DNA fragment 
was amplified from the rat osteoblast cell line, CFK-1 
(Fig. l), the authenticity of this DNA as encoding a rat 
uPAR was confirmed by DNA sequence analysis. 
3.2. Isolation and characterization of rat uPAR cDNA 
Using the amplified rat specific uPAR DNA as a hy- 
bridization probe, ten positive clones were isolated from 
the CFK-1 cDNA library. These rat uPAR clones were 
further purified by secondary screening and subjected to 
nucleotide sequence analysis. By these methods two 1.3- 
kb cDNAs were identified each of which contained the 
full-length coding region of rat uPAR. These cDNAs 
started 11 bp upstream of the initiation codon, were 
followed by a 984 bp open reading frame and extended 
for 275 bp of untranslated sequence in the 3’ noncoding 
region. These two cDNAs (rat uPAR-la and lb) had 
identical restriction maps and each encoded a mature 
peptide of 304 amino acids (Fig. 2). Three silent base 
changes were found between ruPAR-la and ruPAR-lb, 
however, a single base mutation in rat uPAR-lb results 
in a change from Cys to Ser in uPAR-1 b. This amino 
acid change occurs in the critical ligand binding domain 
of the uPAR at amino acid 71 (Fig. 2). 
A comparison of the nucleotide sequences of the iso- 
lated rat uPAR cDNAs showed 67% and 83% homology 
with human and mouse uPAR respectively (Fig. 3). Fur- 
thermore, rat uPAR is 59% and 87% homologous in its 
amino acid sequence to the human and mouse uPAR 
respectively in its ligand binding domain, amino acid 
(l-87). 
3.3. Amplification of an alternatively spliced rat uPAR 
from rat genomic DNA 
Two PCR primers of rat uPAR flanking the unique 
sequence of the alternatively spliced form of mouse 
uPAR were synthesized to attempt to isolate an alterna- 
tively spliced rat uPAR from rat genomic DNA. These 
PCR primers amplified a DNA band of 148 bp corre- 
sponding to our previously isolated receptor isoforms 
uPAR-la and lb. In addition, a 665 bp DNA fragment 
was also amplified from rat CFK-1 genomic DNA using 
these primers (Fig. 4). 
This DNA fragment was subcloned into the 
pBluescript KS(+) vector and sequenced. The sequence 
analysis revealed an open reading frame of 258 bp fol- 
lowed by a stop codon. Although the sequence was ho- 
mologous to the alternately spliced mouse uPAR-2, sub- 
stantial differences were seen at both nucleotide and 
amino acid levels between these two species (Fig. 5). As 
in the mouse alternate splicing of rat uPAR (ruPAR-2) 
occurs in its second domain. 
e ruPAR 
Fig. 1. Amplification of uPAR from rat osteoblasts cell line CFK-1 by 
PCR. 3 pg of total RNA from CFK-1 cells was reverse transcribed as 
described in section 2. Amplification of rat uPAR was done by uPAR 
primers 1 and 2 (described in section 2) and analyzed on a 1.1% DNA 
agarose gel. 
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Fig. 2. Restriction map of rat uPAR. The entire sequence (Fig. 3) was 
obtained from the full length rat uPAR-la and lb. Pstl and SSPI 
restriction sites and amino acids numbers of uPAR protein are indi- 
cated (upper panel). Nucleotide sequencing (lower panel) identified the 
substitution of A in uPAR-lb for T in uPAR-la resulting in Ser instead 
of cys. 
3.4. Partial organization of the rat uPAR gene 
Based on the nucleotide sequence of rat uPAR-la and 
lb, and the sequence of the additional uPAR product 
amplified from genomic DNA it is predicted that uPAR- 
2 arises by alternate splicing. The same exon appears to 
generate two species of mRNA by alternate splicing due 
to the presence of two donor sites. These mRNAs can 
result in the expression of mature proteins of 304 amino 
acids in the case of uPAR-la and 1 b (differing in one 
amino acid as a result of a single base mutation) and 196 
amino acid in the case of rat uPAR-2 (Fig. 6). 
3.5. Expression of alternately spliced ruPAR 
Using flanking PCR primers, expression of alternately 
spliced form of ruPAR was examined in various tissues 
by RT-PCR. This amplification results in two DNA 
bands of 148 bp and 665 bp corresponding to ruPAR-1 
and ruPAR-2, respectively, in rat CFK-1 cells, kidney, 
liver and brain RNA. The authenticity of these amplified 
DNA bands as ruPAR-1 and ruPAR-2 was further con- 
firmed by DNA sequence analysis. 
In the present study we have isolated and character- 
ized three isoforms of the rat UPA receptor. Rat uPAR- 
la and lb each encode a protein with a predicted 24 
amino acid signal peptide followed by a mature protein 
of 304 amino acids. Both receptors have a very high 
cysteine content whose number and location appear to 
dictate the occurrence of three internal repeats as they do 
in the corresponding mouse and human uPARs. A num- 
““I TDziT nrFFIPITLi~-mT*TTFI-TTFCTI wTIml.~ll*mA1.,1111& (7. ,TTAT*lm,TPui ,/~,UrUl,,,, 
*..a” ..I .IT.r._~*/l”,_II.,.T.rr,.. .n I.. .O ,?11 ,,“,,, (~.,l u_l *., .I. ,n A,/ *a ..C .LI n ., , ,/,,” 
“,“,“” . . . . . I. . _ r.. L_.. . . ._ nil .C, .,, . n. . . _ m “,/ _. l,,,D 
Id I-_L_UI_I___C~Cm__Im_I_,___I____L__In_1__mI_,,*, 
“YS” I_ mF XT c.2 cc7 ,?a2 m X. I&G L-A rr. U. C”. ?,A 7.. .A, WA FT, I,., _ .F, u L WA .“I .m , .i I*, _  _ 11(1 
“,,“I. F.lmI~~~“~~~..n.U.~.~.“..m/~1..1.~111../I,Cn.PCP,XL~~7~.n.n,*.,~T~LT,,1, 
**I TF “37 “rr rm An T”T rnT WL hAI m TAT m AU m Tn 7% CA’ *hA AU ,,A .,, ,l& /,l Cl, MT ,1, h, ,j,, 
111m.11, I. ,.I <AA *nl sz Ud .I. n7 I.. TAT ..A 78, 7.F .I< /II Yir Xl I n i* m .m UT TM ?.I “.” .A? TAT _ - I ,11 
I,,.“. ,A. TA. ,.I .&I h. .u m., . ?.,a .?a T”, .*. .a. A.& ..I I.” *, m - rF .~. n* ~,. .,L .p ,~,T ,_ n. /.,. 
11,1111, m1 AI m “TA “I hrr r” (II II 1.4 “Al ,,, A., MA MA uI u* &AA _ _ _ 1u nU nil 
I ,, 
/a,,, 
“IT I. 1, 1 /rril .,, T., II&N” J.llh *I I II* 117 -II m I> P, r, I. ,I. ImT 81 Inn 111 n,TI*I Il.lT, 1!,, 
“,..,, I*,* Llllllnlill .A11?A1111 II*r.,</, ,,I ,mln,.n 1,. ,/, I,, I,. 1,1,,7,,, ,” ,11 ,,r,,“,.**P 1s.” 
Fig. 3. Comparison of nucleotide and amino acid sequences of human, 
mouse and rat uPARs. The sequence of rat uPAR-la is aligned with 
the human and mouse uPAR sequences for comparison. The areas of 
alternate splicing in human, mouse and rat uPARs are marked by +. 
Substitution of T to S in ruPAR-lb is underlined. * indicates identical 
nucleotides and amino acids in human and mouse uPAR. EMBL acces- 
sion no.: X71898 and X71899. 
12 S A. Rabbani et al. I FEBS Letters 338 (1994) 69-74 
Primer A 
Rat (;Tc~~GCG~AGTccT~~~cCr --- --- --- UGOM:~TCTCClJIGTT..2cAGGCGTocAACCAG 141 
Mouse l ** l ** y* '*T l *G CM l TC l ** l TA CAD ATc m MG m rr. l l ** UC AC' 'CA A@2 A** ACA CM CTG A*T :50 
Rat LPAAGSPLGCP---KEISKFQACKQ 
M~~s~**S'*QL'VEIFKSW'Q*TSKRQLN 
Fat ACC rrOCACAGC CAT GCGACAGCACAC TCA GTC CC9 GGAAGT TCl GAG TCACTGGAT CAD Cpc WAG7 GAC CA0 '16 
Mouse CCA CAC AC1 GTC ACA *GA C . . A.' m l . . ..G A.. . . . ..G ..C a. ttt . . . tt. . . . ..T .G* . . . ttt .*. 275 
Rat NSHSHATAXSVPGSSESLDQLBSDQ 
Mouse P H TV T G P T P l l T l R l R l l l l l G l l l 
Rat cAAcn:AoCTAC~oTcoTA~cAcATAcn:~TcATn:TDA~cIyiccTcADDM:AcAATATcDccAccA 191 
MO&e . . . .'c. . . . . . . . . . . . . A.G . . . .C. . . . T.. .*. ..G . . . . . . ttt . . . . . . ..T ..t .*. G.. ..C . . . t.. 303 
Rat ELSYLVVSXILLSFRJD 
Mouse l p . . . . u . p . . . l t at.Jn 
Rat OAOCTCCACACCMOTOACTACZlT~ACOCAOAADAMADADOAA)rG~---CCCAAA~AMm~~wr 363 
Nouse T.A T.. t.. ..T . . . ..T .C. . . . . . . ..A G.. . . . . . . "G . . . .t. ..G GG,J t.. ..t .m Ccp "G T.. t.. 375 
Rat m c?mAcAc?FT TPZ TrT CPA DMAE CCA GM ACT CAT GM OTT CTA TITA'P2 m CO2 GCC CCC TPT ATCATA 438 
Mouse M* l GTmC*+ l mAAMMTCCC l OAAAC l a TAAOCATCTA l * TAT CD* TCG GGC CTC C7T TAT C*A TM CA* 450 
Rat TOOCMA~OAO~~(~AMGTMA~CCTTM~~TAOOO)~OOAA~ACCCTAACTMCA-----------T~ 502 
Mouse *.. 00. .A. --- --- l ** .m p . ..c . . . . . . . . . t.. ..T t.. . . . t.. t.. t.. .G. .AG m m m . . . 51s 
Rat ~~~GG~TPC~GGGGOOCMC TCAACAOCCAOCCCPTAQACGAn:MCCCTCTAACCTLT~CCIC TQC 57: 
MOUSe . . . . . . . . . 'cc m ___ . . . t.e ..A . . . t.. C. t.. ..C 'TA ___ ___ ___ ___ .C. - .t. .m . . . t.. 579 
Rat m IJTC CAC -GG AGC GTG AAG GAC GM CCC TAC ACC AAA GGC TG'; GGC AGT CT? CCC GGA TGC CCG GGC AC;! GCA 65i 
MOU% rT. ..G ..a _+f *.* T** l ** '*T *+G GA' t** l ** CG' it, tt* */t *** l ** +t+ *+* *et "3. **t t+t /** 653 
Rat GGT'I'IC CATAGCAA bb, 
Mouse G;' l ** l ** 1** ** 666 
Primer B 
Fig. 4. Genomic DNA sequence of alternately spliced rat uPAR. The alternately spliced form of rat uPAR @PAR-2) was amplified from genomic 
DNA using PCR primers A and B as described in section 2. The data is aligned with mouse uPAR-2 for comparison. * denotes identical nucleotides 
and amino acids in rat and mouse uPAR-2. The sequence unique to ruPAR-2 (relative to ruPAR-1) is shown in bold. EMBL accession number: 
X-76129. 
ber (43%) of amino acid differences between these rat 
forms and the corresponding human uPAR are found in 
the UPA binding domain (residues l-87). Fewer differ- 
ences (13%) occur in this region between the rat and 
corresponding mouse uPARs. These interspecies amino 
acid substitutions may underlie the apparent increased 
affinity of each receptor for its homologous ligand which 
has been reported at least for mouse and human UPA. 
Furthermore the substitution of Ser in rat uPAR- 1 b for 
Cys in rat uPAR-la at position 71 may have important 
consequences for the ligand-receptor interaction in the 
rat. 
Both mouse and human uPARs are believed to be 
anchored to the cell membrane by a glycosyl-phosphati- 
dyl-inositol (GPI) linkage after removal of a carboxy- 
terminal hydrophobic peptide. The Gly conserved at po- 
sition 275 in rat uPAR-la and 1 b and in muPAR- has 
been suggested to be the site of GPI attachment in these 
species whereas the Gly at position 283 in the huPAR1 
may serve a similar function [lo]. The rat uPARs are also 
highly glycosylated proteins as are the mouse and human 
uPARs. The rat uPARs have 5 putative N-glycosylation 
sites in the same position as in the mouse and human 
receptors and have 2 additional sites in common only 
with the mouse receptor. 
Analysis of genomic DNA has revealed the presence 
of another uPAR isoform which corresponds to uPAR-2 
in the human and mouse. The NH, terminal region of 
uPAR-2 is identical to that of uPAR-la and lb but in- 
cludes a unique carboxyl-terminal peptide of 63 amino 
acids. This appears to be due to alternative splicing from 
the same gene. Thus excision of an intron occurs at 
different positions in uPAR-la and lb versus uPAR-2 
due to two different upstream donor splice sites and the 
same downstream acceptor sites. Comparison of rat 
uPAR-2 with mouse uPAR-2 reveals strong homology 
in both coding and noncoding regions. Furthermore as 
in the mouse, alternative splicing occurs in the second 
internal repeat contrast to the splicing event in human 
uPAR-2 which occurs in the third repeat. Due to the 
presence of a stop codon at nucleotide 258 ruPAR-2 only 
encodes a mature protein of 196 amino acids. As with 
mouse and human uPAR-2, rat uPAR-2 retains the li- 
gand binding site. The sequence unique for these 
isoforms in each case is hydrophillic and lacks a potential 
GPI anchoring site. Consequently as with the other spe- 
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ties of alternatively spliced receptors uPAR-2 may repre- 
sent a water-soluble secreted protein [l 11. 
We and others have observed the expression of uPAR 
isoforms in a variety of tissues, however the potential 
significance of these isoforms is uncertain. Several stud- 
ies in heterologous systems have shown that UPA can 
promote tumor invasions however these studies were 
limited in their scope due to an interspecies blockade of 
UPA actions. In recent studies we have developed a ho- 
mologous rat model to study the role of UPA in tumor 
metastasis associated with prostate cancer. Accumulat- 
ing evidence has suggested an important role for uPAR 
in the process of tumor invasion in a variety of malignan- 
cies. Knowledge of the rat uPAR sequence and availabil- 
ity of a uPAR cDNA will now allow us to characterize 
Rat uPAR Gene 
E-l I E-2 
mRNA1aandlb mRNA 2 
1 
St& 
Protein la 
[F 
CYS 
St& 
1 
Protein 2 
11-871 
1 196 
Protein 1 b 
!T=z!4 
t 
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Fig. 5. Partial organization of the rat uPAR gene. Schematic represen- 
tation of the rat uPAR gene and its mRNA and protein products. The 
coding region of the ruPAR gene consists of two exons E-l and E-2. 
Two alternate donor sites in E-l result in alternative splicing to E-2 and 
consequent variations in the size of the intervening sequence (I). This 
alternative splicing accounts for mRNA la and lb or mRNA-2. A 
single base mutation in E-l appears to account for mRNA la and lb. 
ruPAR-2 -W 
ruPAR-1 q _ 
Fig. 6. Expression of alternately spliced ruPAR. 3 ,ug of total RNA 
from CFK-1 cells rat, kidney, liver and brain were reverse transcribed 
as described in section 2. Amplification of alternately spliced ruPARs 
was performed with flanking primers A and B as described in section 
2. Amplified PCR products were analyzed on a 1.1% DNA agarose gel. 
Amplification of ruPAR-1 and ruPAR-2 are marked by arrows. 
the role played by these receptors in the process of tumor 
invasion and metastasis and to determine the potential 
therapeutic benefit of modulating uPAR levels using 
gene transfer techniques. 
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